نتائج البحث

The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer.

• Authors : Ochoa PT; Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.; Sanchez-Hernandez ES

Subjects: Docetaxel*/Docetaxel*/Docetaxel*/pharmacology ; Docetaxel*/Docetaxel*/Docetaxel*/therapeutic use ; Benzamides*/Benzamides*/Benzamides*/pharmacology

• Source: Cells [Cells] 2025 Oct 09; Vol. 14 (19). Date of Electronic Publication: 2025 Oct 09.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

تفاصيل العنوان

Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data.

• Authors : Wang L; Jilin Cancer Hospital, Changchun, China.; Zhao H

• Source: PloS one [PLoS One] 2025 Sep 12; Vol. 20 (9), pp. e0331979. Date of Electronic Publication: 2025 Sep 12 (Print Publication: 2025).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Effect of Proton-Pump Inhibitor on Survival in Chinese Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Receiving Upfront Combinatorial Docetaxel Treatment.

• Authors : Wong CH; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.; Chiu JT

• Source: Cancers [Cancers (Basel)] 2025 Sep 01; Vol. 17 (17). Date of Electronic Publication: 2025 Sep 01.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print)

تفاصيل العنوان

Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.

• Authors : Sánchez García D; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain.; Grau Mirete B

• Source: Case reports in oncological medicine [Case Rep Oncol Med] 2025 Aug 19; Vol. 2025, pp. 4483379. Date of Electronic Publication: 2025 Aug 19 (Print Publication: 2025).Publisher: Wiley Country of Publication: United States NLM ID: 101581035 Publication Model: eCollection Cited Medium: Print ISSN: 2090-6706

تفاصيل العنوان

Preoperative assessment using a scoring system after neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer: Who can avoid surgery?

• Authors : Kurahashi Y; Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.; Tomita T

Subjects: Esophageal Neoplasms*/Esophageal Neoplasms*/Esophageal Neoplasms*/drug therapy ; Esophageal Neoplasms*/Esophageal Neoplasms*/Esophageal Neoplasms*/pathology ; Esophageal Neoplasms*/Esophageal Neoplasms*/Esophageal Neoplasms*/surgery

• Source: PloS one [PLoS One] 2025 Aug 08; Vol. 20 (8), pp. e0328835. Date of Electronic Publication: 2025 Aug 08 (Print Publication: 2025).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer.

• Authors : Atalan H; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.; Morgan MA

Subjects: Docetaxel*/Docetaxel*/Docetaxel*/therapeutic use ; Docetaxel*/Docetaxel*/Docetaxel*/administration & dosage ; Carboplatin*/Carboplatin*/Carboplatin*/administration & dosage

• Source: Scientific reports [Sci Rep] 2025 Jun 20; Vol. 15 (1), pp. 20130. Date of Electronic Publication: 2025 Jun 20.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions.

• Authors : Postigo-Corrales F; Health Sciences Faculty, Universidad Católica de Murcia (UCAM), 30107 Guadalupe, Spain.; Beltrán-Videla A

Subjects: Docetaxel*/Docetaxel*/Docetaxel*/pharmacology ; Docetaxel*/Docetaxel*/Docetaxel*/therapeutic use ; Antineoplastic Agents*/Antineoplastic Agents*/Antineoplastic Agents*/pharmacology

• Source: International journal of molecular sciences [Int J Mol Sci] 2025 Jul 23; Vol. 26 (15). Date of Electronic Publication: 2025 Jul 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis.

• Authors : Syed A; Department of Biosciences, Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology, Karachi, Pakistan.; Raza H

Subjects: Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/drug therapy ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/mortality ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/pathology

• Source: BMC cancer [BMC Cancer] 2025 Jul 14; Vol. 25 (1), pp. 1173. Date of Electronic Publication: 2025 Jul 14.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Oral Metronomic Delivery of Atorvastatin and Docetaxel via Transporter-Targeted Nanoemulsions Enhances Antitumor Efficacy and Immune Modulation in Colon Cancer.

• Authors : Subedi L; Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam 58554, Republic of Korea.; Biomedicine Cutting Edge Formulation Technology Center, Mokpo National University, Jeonnam 58554, Republic of Korea.

• Source: Pharmaceutics [Pharmaceutics] 2025 Jul 02; Vol. 17 (7). Date of Electronic Publication: 2025 Jul 02.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print)

تفاصيل العنوان

The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience.

• Authors : Cai Q; Melanoma and Sarcoma Medical Oncology Unit, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Xu B

Subjects: Docetaxel*/Docetaxel*/Docetaxel*/administration & dosage ; Docetaxel*/Docetaxel*/Docetaxel*/adverse effects ; Docetaxel*/Docetaxel*/Docetaxel*/therapeutic use

• Source: BMC cancer [BMC Cancer] 2025 Jul 01; Vol. 25 (1), pp. 1030. Date of Electronic Publication: 2025 Jul 01.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان